Boston Scientific Completes Acquisition of Valencia Technologies to Expand Urinary Incontinence Portfolio

The deal, first announced in January, allows Boston Scientific to compete directly with Medtronic in a market analysts describe as highly under-penetrated.

Boston Scientific has officially closed its acquisition of Valencia Technologies, the maker of the eCoin tibial nerve stimulator for urinary urge incontinence, the company announced on LinkedIn last week.

The deal, first announced in January, allows Boston Scientific to compete directly with Medtronic in a market analysts describe as highly under-penetrated.

Valencia Technologies received premarket approval for eCoin in 2022. The device, implanted near the ankle, periodically stimulates the tibial nerve to regulate bladder-brain communication. Clinical trials reported that 68% of participants achieved at least a 50% reduction in urinary urge incontinence episodes.

The acquisition comes amid growing competition in the segment. Bluewind’s Revi device received authorization in 2023, while Medtronic’s Altaviva gained approval last year. Analysts at Leerink Partners have highlighted Altaviva’s battery life as a competitive advantage, and Medtronic CFO Thierry Piéton recently described urinary incontinence as a “massive opportunity.”

Boston Scientific plans to leverage its commercial expertise from existing urology products, including the Axonics sacral neuromodulation system, which treats overactive bladder and fecal incontinence, to expand eCoin adoption. RBC Capital Markets analysts noted strong physician interest in eCoin, highlighting its traction as an alternative to sacral neuromodulation.

Analysts project near-term growth for the tibial nerve stimulation market, supported by market development, reimbursement, and increased physician and patient education, potentially driving a sustained double-digit CAGR as adoption rises.

Valencia Technologies is expected to deliver net revenue of $10 million in 2025, with a projected 20% year-over-year growth rate. With Boston Scientific’s ownership, analysts believe the market for eCoin could expand further, capitalizing on its under-penetration and physician interest in alternative urinary incontinence treatments.

Stay tuned for more such updates on Digital Health News